Advertisement

Challenging the Therapy/Enhancement Distinction in CRISPR Gene Editing

  • Arvin M. Gouw
Chapter

Abstract

CRISPR science enables genomic engineering that has major implications in disease prevention and therapy, but also in various non-human applications. Despite CRISPR’s great potential, there are major scientific concerns that must be further investigated: off-target effects, chimerism, unknown epigenetic effects, and long term on-target effects. Moreover, there are also social justice concerns regarding the democratization of CRISPR technology due to its highly pragmatic and executable nature. This makes policy development to regulate CRISPR very challenging. Historically in the United States, genomic engineering policy has been under the FDA’s jurisdiction. However, multiple institutional committees have reported guidelines on CRISPR policy, including transnational collaborations that also respect cultural contextual differences. The FDA and institutional guidelines share a common prescription to allow CRISPR editing for therapeutic purposes only and not for enhancement. Unfortunately, the very notions of therapy and enhancements are unclear, because they depend on one’s notion of nature and what normal means. Understanding of the baseline “normal” as a statistical average overcomes the need to unify various philosophical views on “nature”. Moreover, the medical statistical view of “normal”, “disease”, integrates personal safety issues with communal equity social justice considerations. In conclusion, regulations development of CRISPR editing requires not only additional scientific research but also a rethinking of the notion of “normal” in relation to equity and access.

Notes

Acknowledgments

I am grateful for the support of the Center for Theology and the Natural Sciences (CTNS), especially Dr. Ted Peters. Moreover, I am grateful for the valuable discussions with colleagues from CTNS, Harvard Divinity School Center for Science, Religion and Culture (SRC) and the Sinai and Synapses Fellowship at the National Jewish Center for Learning and Leadership (CLAL). Finally, I would like to thank Danielle Fumagalli for providing valuable feedback on multiple versions of this chapter.

References

  1. 2017. The Future of Human Genome Editing. Nature Genetics 49 (5): 653. doi:  https://doi.org/10.1038/ng.3860.
  2. ACMG Board of Directors. 2017. Genome Editing in Clinical Genetics: Points to Consider-a Statement of the American College of Medical Genetics and Genomics. Genetics in Medicine 19 (7): 723–724.  https://doi.org/10.1038/gim.2016.195.CrossRefGoogle Scholar
  3. Alper, J.S. 1996. Genetic Complexity in Single Gene Diseases. BMJ 312 (7025): 196–197.CrossRefGoogle Scholar
  4. Anderson, W.F. 1992. The June RAC Meeting. Human Gene Therapy 3 (5): 459–460.  https://doi.org/10.1089/hum.1992.3.5-459.CrossRefGoogle Scholar
  5. Barrangou, R., C. Fremaux, H. Deveau, M. Richards, P. Boyaval, S. Moineau, D.A. Romero, and P. Horvath. 2007. CRISPR Provides Acquired Resistance Against Viruses in Prokaryotes. Science 315 (5819): 1709–1712.  https://doi.org/10.1126/science.1138140.CrossRefGoogle Scholar
  6. Bosley, K.S., M. Botchan, A.L. Bredenoord, D. Carroll, R.A. Charo, E. Charpentier, R. Cohen, J. Corn, J. Doudna, G. Feng, H.T. Greely, R. Isasi, W. Ji, J.S. Kim, B. Knoppers, E. Lanphier, J. Li, R. Lovell-Badge, G.S. Martin, J. Moreno, L. Naldini, M. Pera, A.C. Perry, J.C. Venter, F. Zhang, and Q. Zhou. 2015. CRISPR Germline Engineering--the Community Speaks. Nature Biotechnology 33 (5): 478–486.  https://doi.org/10.1038/nbt.3227.CrossRefGoogle Scholar
  7. Boyd, K.M. 2000. Disease, Illness, Sickness, Health, Healing and Wholeness: Exploring Some Elusive Concepts. Medical Humanities 26 (1): 9–17.CrossRefGoogle Scholar
  8. Carbon, J., T.E. Shenk, and P. Berg. 1975. Construction in Vitro of Mutants of Simian Virus 40: Insertion of a Poly(dA-dT) Segment at the Hemophilus Parainfluenza II Restriction Endonuclease Cleavage Site. Journal of Molecular Biology 98 (1): 1–15.CrossRefGoogle Scholar
  9. Coates, Peter A. 1998. Nature: Western Attitudes Since Ancient Times. Berkeley: University of California Press.Google Scholar
  10. Cong, L., F.A. Ran, D. Cox, S. Lin, R. Barretto, N. Habib, P.D. Hsu, X. Wu, W. Jiang, L.A. Marraffini, and F. Zhang. 2013. Multiplex Genome Engineering Using CRISPR/Cas Systems. Science 339 (6121): 819–823.  https://doi.org/10.1126/science.1231143.CrossRefGoogle Scholar
  11. Crawford, M. 1987. RAC Recommends Easing Some Recombinant DNA Guidelines. Science 235 (4790): 740–741.CrossRefGoogle Scholar
  12. Cyranoski, D. 2015. Gene-edited ‘Micropigs’ to be Sold as Pets at Chinese Institute. Nature 526 (7571): 18.  https://doi.org/10.1038/nature.2015.18448.CrossRefGoogle Scholar
  13. de Lecuona, I., M. Casado, G. Marfany, M. Lopez Baroni, and M. Escarrabill. 2017. Gene Editing in Humans: Towards a Global and Inclusive Debate for Responsible Research. The Yale Journal of Biology and Medicine 90 (4): 673–681.Google Scholar
  14. Deveau, H., R. Barrangou, J.E. Garneau, J. Labonte, C. Fremaux, P. Boyaval, D.A. Romero, P. Horvath, and S. Moineau. 2008. Phage Response to CRISPR-encoded Resistance in Streptococcus thermophilus. Journal of Bacteriology 190 (4): 1390–1400.  https://doi.org/10.1128/JB.01412-07.CrossRefGoogle Scholar
  15. Dhanapala, P., T. Doran, M.L. Tang, and C. Suphioglu. 2015. Production and Immunological Analysis of IgE Reactive Recombinant Egg White Allergens Expressed in Escherichia coli. Molecular Immunology 65 (1): 104–112.  https://doi.org/10.1016/j.molimm.2015.01.006.CrossRefGoogle Scholar
  16. Ethics, Standards. 2001. Genethics. Gene Therapy or Genetic Enhancement: Does it Make a Difference? Virtual Mentor:E5.Google Scholar
  17. Fears, R., and V. Ter Meulen. 2017. How Should the Applications of Genome Editing be Assessed and Regulated? eLife 6.  https://doi.org/10.7554/eLife.26295.
  18. Goff, S.P., and P. Berg. 1976. Construction of Hybrid Viruses Containing SV40 and Lambda Phage DNA Segments and their Propagation in Cultured Monkey Cells. Cell 9 (4 PT 2): 695–705.CrossRefGoogle Scholar
  19. Gottweis, H. 2005. Regulating Genomics in the 21st Century: From Logos to Pathos? Trends in Biotechnology 23 (3): 118–121.  https://doi.org/10.1016/j.tibtech.2005.01.002.CrossRefGoogle Scholar
  20. Grant, E.V. 2016. FDA Regulation of Clinical Applications of CRISPR-CAS Gene-Editing Technology. Food and Drug Law Journal 71 (4): 608–633.Google Scholar
  21. Guo, R., H. Wang, J. Cui, G. Wang, W. Li, and J.F. Hu. 2015. Inhibition of HIV-1 Viral Infection by an Engineered CRISPR Csy4 RNA Endoribonuclease. PLoS One 10 (10): e0141335.  https://doi.org/10.1371/journal.pone.0141335.CrossRefGoogle Scholar
  22. Horvath, P., D.A. Romero, A.C. Coute-Monvoisin, M. Richards, H. Deveau, S. Moineau, P. Boyaval, C. Fremaux, and R. Barrangou. 2008. Diversity, Activity, and Evolution of CRISPR loci in Streptococcus thermophilus. Journal of Bacteriology 190 (4): 1401–1412.  https://doi.org/10.1128/JB.01415-07.CrossRefGoogle Scholar
  23. Hu, W., R. Kaminski, F. Yang, Y. Zhang, L. Cosentino, F. Li, B. Luo, D. Alvarez-Carbonell, Y. Garcia-Mesa, J. Karn, X. Mo, and K. Khalili. 2014. RNA-Directed Gene Editing Specifically Eradicates Latent and Prevents New HIV-1 Infection. Proceedings of the National Academy of Sciences of the United States of America 111 (31): 11461–11466.  https://doi.org/10.1073/pnas.1405186111.CrossRefGoogle Scholar
  24. Hutter, G., J. Bodor, S. Ledger, M. Boyd, M. Millington, M. Tsie, and G. Symonds. 2015. CCR5 Targeted Cell Therapy for HIV and Prevention of Viral Escape. Viruses 7 (8): 4186–4203.  https://doi.org/10.3390/v7082816.CrossRefGoogle Scholar
  25. Ishino, Y., H. Shinagawa, K. Makino, M. Amemura, and A. Nakata. 1987. Nucleotide Sequence of the Iap Gene, Responsible for Alkaline Phosphatase Isozyme Conversion in Escherichia coli, and Identification of the Gene Product. Journal of Bacteriology 169 (12): 5429–5433.CrossRefGoogle Scholar
  26. Jinek, M., K. Chylinski, I. Fonfara, M. Hauer, J.A. Doudna, and E. Charpentier. 2012. A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity. Science 337 (6096): 816–821.  https://doi.org/10.1126/science.1225829.CrossRefGoogle Scholar
  27. Jinek, M., A. East, A. Cheng, S. Lin, E. Ma, and J. Doudna. 2013. RNA-Programmed Genome Editing in Human Cells. eLife 2: e00471.  https://doi.org/10.7554/eLife.00471.CrossRefGoogle Scholar
  28. Juarrero, Alicia. 1999. Dynamics in Action: Intentional Behavior as a Complex System. Cambridge, MA: MIT Press.Google Scholar
  29. Kaminski, R., Y. Chen, T. Fischer, E. Tedaldi, A. Napoli, Y. Zhang, J. Karn, W. Hu, and K. Khalili. 2016a. Corrigendum: Elimination of HIV-1 Genomes from Human T-lymphoid Cells by CRISPR/Cas9 Gene Editing. Scientific Reports 6: 28213.  https://doi.org/10.1038/srep28213.CrossRefGoogle Scholar
  30. ———. 2016b. Elimination of HIV-1 Genomes from Human T-lymphoid Cells by CRISPR/Cas9 Gene Editing. Scientific Reports 6: 22555.  https://doi.org/10.1038/srep22555.CrossRefGoogle Scholar
  31. Kosuri, S., N. Eroshenko, E.M. Leproust, M. Super, J. Way, J.B. Li, and G.M. Church. 2010. Scalable Gene Synthesis by Selective Amplification of DNA Pools from High-Fidelity Microchips. Nature Biotechnology 28 (12): 1295–1299.  https://doi.org/10.1038/nbt.1716.CrossRefGoogle Scholar
  32. Lagay, F. 2001. Gene Therapy or Genetic Enhancement: Does It Make a Difference? Virtual Mentor 3 (2).  https://doi.org/10.1001/virtualmentor.2001.3.2.gnth1-0102.
  33. Ledford, H. 2015a. Biohackers Gear Up for Genome Editing. Nature 524 (7566): 398–399.  https://doi.org/10.1038/524398a.CrossRefGoogle Scholar
  34. ———. 2015b. CRISPR, the Disruptor. Nature 522 (7554): 20–24.  https://doi.org/10.1038/522020a.CrossRefGoogle Scholar
  35. Liang, P., Y. Xu, X. Zhang, C. Ding, R. Huang, Z. Zhang, J. Lv, X. Xie, Y. Chen, Y. Li, Y. Sun, Y. Bai, Z. Songyang, W. Ma, C. Zhou, and J. Huang. 2015. CRISPR/Cas9-mediated Gene Editing in Human Tripronuclear Zygotes. Protein & Cell 6 (5): 363–372.  https://doi.org/10.1007/s13238-015-0153-5.CrossRefGoogle Scholar
  36. Lillico, S.G., C. Proudfoot, T.J. King, W. Tan, L. Zhang, R. Mardjuki, D.E. Paschon, E.J. Rebar, F.D. Urnov, A.J. Mileham, D.G. McLaren, and C.B. Whitelaw. 2016. Mammalian Interspecies Substitution of Immune Modulatory Alleles by Genome Editing. Scientific Reports 6: 21645.  https://doi.org/10.1038/srep21645.CrossRefGoogle Scholar
  37. Long, C., J.R. McAnally, J.M. Shelton, A.A. Mireault, R. Bassel-Duby, and E.N. Olson. 2014. Prevention of Muscular Dystrophy in Mice by CRISPR/Cas9-Mediated Editing of Germline DNA. Science 345 (6201): 1184–1188.  https://doi.org/10.1126/science.1254445.CrossRefGoogle Scholar
  38. Lustig, B.A., B.A. Brody, and G.P. McKenny. 2008. Altering Nature, 2 vols, Philosophy and Medicine. Dordrecht: Springer.Google Scholar
  39. Mali, P., K.M. Esvelt, and G.M. Church. 2013a. Cas9 as a Versatile Tool for Engineering Biology. Nature Methods 10 (10): 957–963.  https://doi.org/10.1038/nmeth.2649.CrossRefGoogle Scholar
  40. Mali, P., L. Yang, K.M. Esvelt, J. Aach, M. Guell, J.E. DiCarlo, J.E. Norville, and G.M. Church. 2013b. RNA-guided Human Genome Engineering via Cas9. Science 339 (6121): 823–826.  https://doi.org/10.1126/science.1232033.CrossRefGoogle Scholar
  41. Merrill, R.A., and B.J. Rose. 2001. FDA Regulation of Human Cloning: Usurpation or Statesmanship? Harvard Journal of Law & Technology 15 (1): 85–148.Google Scholar
  42. Mojica, F.J., C. Ferrer, G. Juez, and F. Rodriguez-Valera. 1995. Long Stretches of Short Tandem Repeats are Present in the Largest Replicons of the Archaea Haloferax mediterranei and Haloferax volcanii and Could Be Involved in Replicon Partitioning. Molecular Microbiology 17 (1): 85–93.CrossRefGoogle Scholar
  43. Morison, Benjamin. 2002. On Location: Aristotle’s Concept of Place, Oxford Aristotle Studies. New York: Oxford University Press.CrossRefGoogle Scholar
  44. Mulligan, R.C., B.H. Howard, and P. Berg. 1979. Synthesis of Rabbit Beta-Globin in Cultured Monkey Kidney Cells Following Infection with a SV40 Beta-Globin Recombinant Genome. Nature 277 (5692): 108–114.CrossRefGoogle Scholar
  45. Oye, K.A., and K.M. Esvelt. 2014. Gene Drives Raise Dual-Use Concerns – Response. Science 345 (6200): 1010–1011.  https://doi.org/10.1126/science.345.6200.1010-c.CrossRefGoogle Scholar
  46. Oye, K.A., K. Esvelt, E. Appleton, F. Catteruccia, G. Church, T. Kuiken, S.B. Lightfoot, J. McNamara, A. Smidler, and J.P. Collins. 2014. Biotechnology. Regulating Gene Drives. Science 345 (6197): 626–628.  https://doi.org/10.1126/science.1254287.CrossRefGoogle Scholar
  47. Rainsbury, J.M. 2000. Biotechnology on the RAC: FDA/NIH Regulation of Human Gene Therapy. Food and Drug Law Journal 55 (4): 575–600.Google Scholar
  48. Rosenberg, Alexander. 2012. Philosophy of Science: A Contemporary Introduction, Routledge Contemporary Introductions to Philosophy. 3rd ed. New York: Routledge.Google Scholar
  49. Sampson, T.R., and D.S. Weiss. 2013. Cas9-dependent Endogenous Gene Regulation is Required for Bacterial Virulence. Biochemical Society Transactions 41 (6): 1407–1411.  https://doi.org/10.1042/BST20130163.CrossRefGoogle Scholar
  50. Sampson, T.R., S.D. Saroj, A.C. Llewellyn, Y.L. Tzeng, and D.S. Weiss. 2013. A CRISPR/Cas System Mediates Bacterial Innate Immune Evasion and Virulence. Nature 497 (7448): 254–257.  https://doi.org/10.1038/nature12048.CrossRefGoogle Scholar
  51. Sancho, M., and T.A. Rodriguez. 2014. Selecting for Fitness in Mammalian Development. Cell Cycle 13 (1): 9–10.  https://doi.org/10.4161/cc.27026.CrossRefGoogle Scholar
  52. Sander, J.D., E.J. Dahlborg, M.J. Goodwin, L. Cade, F. Zhang, D. Cifuentes, S.J. Curtin, J.S. Blackburn, S. Thibodeau-Beganny, Y. Qi, C.J. Pierick, E. Hoffman, M.L. Maeder, C. Khayter, D. Reyon, D. Dobbs, D.M. Langenau, R.M. Stupar, A.J. Giraldez, D.F. Voytas, R.T. Peterson, J.R. Yeh, and J.K. Joung. 2011. Selection-Free Zinc-Finger-Nuclease Engineering by Context-Dependent Assembly (CoDA). Nature Methods 8 (1): 67–69.  https://doi.org/10.1038/nmeth.1542.CrossRefGoogle Scholar
  53. Shaberman, B. 2017. A Retinal Research Nonprofit Paves the Way for Commercializing Gene Therapies. Human Gene Therapy 28 (12): 1118–1121.  https://doi.org/10.1089/hum.2017.29058.bsh.CrossRefGoogle Scholar
  54. Shan, Q., Y. Wang, J. Li, and C. Gao. 2014. Genome Editing in Rice and Wheat Using the CRISPR/Cas System. Nature Protocols 9 (10): 2395–2410.  https://doi.org/10.1038/nprot.2014.157.CrossRefGoogle Scholar
  55. Skyrms, Brian. 2012. From Zeno to Arbitrage: Essays on Quantity, Coherence, and Induction. 1st ed. Oxford: Oxford University Press.CrossRefGoogle Scholar
  56. Sorek, R., C.M. Lawrence, and B. Wiedenheft. 2013. CRISPR-mediated Adaptive Immune Systems in Bacteria and Archaea. Annual Review of Biochemistry 82: 237–266.  https://doi.org/10.1146/annurev-biochem-072911-172315.CrossRefGoogle Scholar
  57. Terns, M.P., and R.M. Terns. 2011. CRISPR-Based Adaptive Immune Systems. Current Opinion in Microbiology 14 (3): 321–327.  https://doi.org/10.1016/j.mib.2011.03.005.CrossRefGoogle Scholar
  58. The Lancet. 2018. Editing the Human Genome: Balancing Safety and Regulation. Lancet 391 (10119): 402.  https://doi.org/10.1016/S0140-6736(18)30153-3.CrossRefGoogle Scholar
  59. Tillich, P. 1961. The Meaning of Health. Perspectives in Biology and Medicine 5: 92–100.CrossRefGoogle Scholar
  60. Velazquez, A. 1997. Gene-Nutrient Interactions in Single-gene Defects and Polygenic Diseases: Methodologic Considerations. World Review of Nutrition and Dietetics 80: 145–164.CrossRefGoogle Scholar
  61. Villarreal, L.P., and P. Berg. 1977. Hybridization in Situ of SV40 Plaques: Detection of Recombinant SV40 Virus Carrying Specific Sequences of Nonviral DNA. Science 196 (4286): 183–185.CrossRefGoogle Scholar
  62. Weatherall, D.J. 2000. Single Gene Disorders or Complex Traits: Lessons from the Thalassaemias and Other Monogenic Diseases. BMJ 321 (7269): 1117–1120.CrossRefGoogle Scholar
  63. White, M.K., and K. Khalili. 2016. CRISPR/Cas9 and Cancer Targets: Future Possibilities and Present Challenges. Oncotarget 7 (11): 12305–12317.  https://doi.org/10.18632/oncotarget.7104.CrossRefGoogle Scholar
  64. White, M.K., W. Hu, and K. Khalili. 2015. The CRISPR/Cas9 Genome Editing Methodology as a Weapon Against Human Viruses. Discovery Medicine 19 (105): 255–262.Google Scholar
  65. Whitworth, K.M., R.R. Rowland, C.L. Ewen, B.R. Trible, M.A. Kerrigan, A.G. Cino-Ozuna, M.S. Samuel, J.E. Lightner, D.G. McLaren, A.J. Mileham, K.D. Wells, and R.S. Prather. 2016. Gene-Edited Pigs are Protected from Porcine Reproductive and Respiratory Syndrome Virus. Nature Biotechnology 34 (1): 20–22.  https://doi.org/10.1038/nbt.3434.CrossRefGoogle Scholar
  66. Willgoos, C. 2001. FDA Regulation: An Answer to the Questions of Human Cloning and Germline Gene Therapy. American Journal of Law & Medicine 27 (1): 101–124.Google Scholar
  67. Wilmut, I. 2003. Dolly-her Life and Legacy. Cloning and Stem Cells 5 (2): 99–100.  https://doi.org/10.1089/153623003322234687.CrossRefGoogle Scholar
  68. Wollebo, H.S., A. Bellizzi, R. Kaminski, W. Hu, M.K. White, and K. Khalili. 2015. CRISPR/Cas9 System as an Agent for Eliminating Polyomavirus JC Infection. PLoS One 10 (9): e0136046.  https://doi.org/10.1371/journal.pone.0136046.CrossRefGoogle Scholar
  69. Zhang, Y., C. Yin, T. Zhang, F. Li, W. Yang, R. Kaminski, P.R. Fagan, R. Putatunda, W.B. Young, K. Khalili, and W. Hu. 2015. CRISPR/gRNA-Directed Synergistic Activation Mediator (SAM) Induces Specific, Persistent and Robust Reactivation of the HIV-1 Latent Reservoirs. Scientific Reports 5: 16277.  https://doi.org/10.1038/srep16277.CrossRefGoogle Scholar

Copyright information

© The Author(s) 2018

Authors and Affiliations

  • Arvin M. Gouw
    • 1
  1. 1.Harvard Divinity SchoolCambridgeUSA

Personalised recommendations